A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of functional dyspepsia.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2015
At a glance
- Drugs Espindolol (Primary)
- Indications Non-ulcer dyspepsia
- Focus Therapeutic Use
- Sponsors AGI Therapeutics
- 11 Jul 2015 Status changed from completed to discontinued as per European Clinical Trials Database record.
- 11 Jul 2011 New trial record